Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027 Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent Advancing clinical candidates for the treatment of hantavirus infections NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today provided recent business highlights and reported financial results for the quarter ended March 31, 2026. The highlights include updates on the Company’s lead program, tivoxavir marboxil (TXM), in development for influenza prophylaxis,...

New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize...

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic corporate update. Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board, commented, “Following recent changes in executive management, the Company has conducted a review of its development programs, operating resources and ongoing corporate initiatives. While this transition period involves certain operational and organizational adjustments, the Company remains focused on supporting and advancing its therapeutic and research activities.” “Currently we are evaluating our Decoy platform, including its preclinical data and underlying scientific rationale,...

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026 BASECAMP remains on track to complete enrollment in Q3 2026 The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years. Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027TORONTO, May 15, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026. “The first quarter of 2026 was a productive time for Satellos. We raised $57M, providing runway to meet all planned milestones through the end of 2027, uplisted...

NEWPORT BEACH, Calif., May 15, 2026 (GLOBE NEWSWIRE) — PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, has filed its Quarterly Report on Form 10-Q (the “Quarterly Report”) for the three months ended March 31, 2026, with the U.S. Securities and Exchange Commission (“SEC”). The Quarterly Report is available on the SEC’s website at www.sec.gov under the Company’s filings. Q1 2026 was a quarter of meaningful balance sheet growth, driven by the Company’s financing and M&A activities, including the closing of the SVM Machining Inc. (“SVM”) acquisition. SVM is a Northern California-based precision machining and manufacturing services company serving medical, aerospace, biotech & pharmaceutical, semiconductor, and transportation markets. Balance Sheet HighlightsTotal assets increased...

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June Sales force expansion to 148 representatives completed Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients against allergic reactions that could lead to anaphylaxis, today announced financial results for the first quarter of 2026 and provided an update on the continued commercialization of neffy®...

A total of 13,215 hotels or 1,303,563 hotel rooms in operation as of March 31, 2026. Hotel turnover1 increased 17.4% year-over-year to RMB26.4 billion in the first quarter of 2026. Excluding H World International (“HWI”)2, hotel turnover from the H World China (“HWC”)3 segment increased 18.0% year-over-year in the first quarter of 2026. Hotel turnover from the HWI segment increased 9.6% year-over-year in the first quarter of 2026. Revenue in the first quarter of 2026 increased 11.1% year-over-year to RMB6.0 billion (US$870 million)4. Manachised and franchised (“M&F”) revenue increased 20.3% year-over-year to RMB3.0 billion (US$436 million) over the same period. Revenue from the HWC segment in the first quarter of 2026 was RMB5.0 billion, which increased 12.4% year-over-year; and HWI segment revenue in the first quarter of 2026 was...

Press release Communiqué de presseSyensqo first quarter 2026 results Net sales of €1.4 billion, increased 5% sequentially, led by Specialty Polymers and Novecare; Underlying EBITDA of €251 million, increased 6% sequentially, led by Specialty Polymers; Full year 2026 underlying EBITDA outlook unchanged, with capital expenditure lowered by up to €50 million Brussels, May 15, 2026, 7.00am CET Q1 2026 HighlightsNet sales of €1.4 billion reflect stable overall year-on-year volumes, offset by the adverse impact of foreign exchange movements. On a sequential basis, net sales increased 5%, driven by higher volumes led by Specialty Polymers and Novecare, while pricing remained stable; Gross profit of €444 million reflects the year-on-year impact of foreign exchange movements on net sales as well as unfavorable product mix, resulting in...

VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) — American Hotel Income Properties REIT LP (“AHIP”, or the “Company”) (TSX: HOT.UN, TSX: HOT.U, TSX: HOT.DB. V), today announced its financial results for the three months ended March 31, 2026. All amounts presented in this news release are in United States dollars (“U.S. dollars”) unless otherwise indicated. 2026 FIRST QUARTER HIGHLIGHTSSame Property ADR(1) was $142 for the first quarter of 2026 an increase of 2.2% compared to $139 for the same period of 2025. Same Property Occupancy(1) was 68.7% for the first quarter of 2026, a decrease of 30 bps compared to 69.0% for the same period of 2025. Same Property RevPAR(1) was $98 for the first quarter of 2026, an increase of 2.1% compared to $96 for the same period of 2025. Same property NOI(1) was $8.7 million for the first...

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) — Vroom, Inc. (Nasdaq:VRM) today announced financial results for the first quarter ended March 31, 2026. HIGHLIGHTS OF FIRST QUARTER 2026$98.4 million stockholders’ equity as of March 31, 2026 and $86.5 million tangible book value(1) as of March 31, 2026 $56.4 million consolidated total available liquidity(2) as of March 31, 2026, consisting of:$14.5 million cash and cash equivalents         $14.9 million of liquidity available to UACC under the warehouse credit facilities $27.0 million of available liquidity from delayed draw facility, further strengthening our liquidity position to execute our long-term strategy$22.5 million preferred stock issued by Vroom Automotive LLC to SPE Holdings in January 2026 $(19.6) million net loss attributable to controlling interest and common...